A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...

Explore the benefits of supportive care in large B-cell lymphoma treatment. Learn how it can ease symptoms, boost quality of life, and more.

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

San Carlos, California Thursday, January 8, 2026, 13:00 Hrs [IST] ...